Show Summary Details
Page of

Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT) 

Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT)
Chapter:
Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT)
Author(s):

Daniel Barron

, and Noah Capurso

DOI:
10.1093/med/9780190625085.003.0046
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 August 2019

Patients with schizophrenia have a 50% risk of a suicide attempt during their life, with a nearly an estimated 10% risk of completed suicide. Decreasing this risk is an urgent clinical concern. This chapter provides a summary of a landmark study on how to reduce suicidality in patients with schizophrenia, specifically whether clozapine reduces suicidal events in patients with schizophrenia. This chapter describes the outline of the study, including fundings sources, study locations, the patient population and how many were studied, the study design and intervention through to follow-up, endpoints, results, and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.